Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 28;10(6):1027-1033.
doi: 10.14218/JCTH.2021.00317. Epub 2022 Feb 28.

Development and Validation of a Nomogram for Prediction of the Risk of MAFLD in an Overweight and Obese Population

Di Song  1 , Qian Ge  2 , Ming Chen  1 , Song Bai  1 , Xiaoshu Lai  1 , Gege Huang  2 , Mengmeng Liu  1 , Miaofang Lin  1 , Jinfeng Xu  1 , Fajin Dong  1
Affiliations

Development and Validation of a Nomogram for Prediction of the Risk of MAFLD in an Overweight and Obese Population

Di Song et al. J Clin Transl Hepatol. .

Abstract

Background and aims: Metabolic associated fatty liver disease (MAFLD) is a serious condition, and a simple method is needed for practitioners to identify patients with the disease and have a high risk of disease progression.

Methods: We developed and validated a nomogram for fatty liver disease and reclassified the risk factors for MAFLD. The development cohort had 335 patients who received bioelectrical impedance analysis and liver ultrasound attenuation measurements at Shenzhen People's Hospital between September 2020 and June 2021. The validation cohort had 200 patients from other hospitals who received the same evaluation. A random forest procedure and binary logistic analysis were used to screen for risk factors, establish a fatty liver disease predictive model, and forecast the risk of MAFLD. The performance of the nomogram was evaluated by measurement of discrimination, calibration, and clinical usefulness.

Results: The nomogram provided good predictions in a model that included body mass index (BMI) and waist circumference. The areas under the curve of the nomogram were 0.793 in the development cohort and 0.774 in the validation cohort. The nomogram performed well for calibration, category-free net reclassification improvement, and integrated discrimination improvement. Decision curve analysis indicated the nomogram performed better than BMI for predicting net outcome.

Conclusions: The nomogram was an effective screening tool for fatty liver disease, and for those overweight individuals, may help physicians make appropriate decisions regarding treatment of MAFLD.

Keywords: Body composition; Liver ultrasound attenuation, LiSA; MAFLD; Nomogram; Obesity.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interests related to this publication.

Figures

Fig. 1
Fig. 1. Representative liver ultrasound attenuation (LiSA) measurements of a patient (A) without fatty liver and a patient (B) with fatty liver.
Fig. 2
Fig. 2. Nomogram for prediction of fatty liver and MAFLD.
Procedure: First, identify the waist circumference (WC), draw a vertical line to the points axis, and determine the score. Second, repeat this process for BMI. Third, sum the two scores, and identify this sum on the total points axis. Fourth, draw a vertical line from the total points” axis to the probability axis to determine the probability. When a subject has a BMI >24 and a WC ≥90 cm (men) or ≥80 cm (women), the predicted probability of fatty liver is the predicted probability of MAFLD. MAFLD, metabolic associated fatty liver disease.
Fig. 3
Fig. 3. Decision curve analysis of the validation cohort.
BMI, body mass index; WC, waist circumference.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2020;5(2):167–228. doi: 10.1016/S2468-1253(19)30342-5. - DOI - PMC - PubMed
    1. Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389–398. doi: 10.1016/S2468-1253(19)30039-1. - DOI - PubMed
    1. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi: 10.1016/j.jhep.2020.03.039. - DOI - PubMed
    1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766–781. doi: 10.1016/S0140-6736(14)60460-8. - DOI - PMC - PubMed
    1. Luis J, Coronado-Cáceres, Rabadán-Chávez G, Mojica L, Stampa IJF. Cocoa (Theobroma cacao L.) Seed Proteins’ Anti-Obesity Potential through Lipase Inhibition Using In Silico, In Vitro and In Vivo Models. Foods. 2020;9(10):1359. doi: 10.3390/foods9101359. - DOI - PMC - PubMed